PIEZO1 and channelopathy: This suggests that in the future utilizing proteasomal inhibitors in use in the clinic in combination with a precision medicine-based approach we may be able to rectify the mis-localization and reduced function of Piezo1 channels associated with a subset of Piezo1-channel mediated channelopathies.